Aggregated price index with volume information
Summary:
- Antibiotic Developers stocks up 0.6% on average while median return up 0.8% in a day
- Antibiotic Developers stocks down 1.0% on average while median return down -0.0% in a week
- Antibiotic Developers stocks down 2.9% on average while median return down 6.6% in a month
- When average return is significantly different from median return, this implies an asymmetry - composite return is driven by some outliners.
Aggregated price index (close) is based on equal weighted constituencies returns. Average short volume and average total volumes are averaged across all volume data among constituencies.
- 1M winners are : Winners for past month are $SMMT 8.1%
- 1M losers are : Losers for past month are $SPRO -16.0%
- 1W winners are : Winners for past week are
- 1W losers are : Losers for past week are $MRK -3.2%
Correlation Analysis
Index correlation analysis
Correlation for the past month is -3.9%, for the past 3 months is 1.9%
In the past month for a 5 days rolling window, the highest corrrelation is 26.1%, the lowest correlation is -32.7%, the latest correlation is -18.0%
When a correlation deviated from the normal level and goes lower or even negative, it indicates some of stocks have deviated from the normal direction of the group. The deviation could reverse if long term level of correlation was at a higher level. It creates trading opportunities and deserves study whether the deviation is idiosyncratic or systematic.
Among pairwise correlation, the highest correlation is 22.0% between MRK and SPRO
The lowest correlation is -21.1% between SMMT and SPRO
CAMBRIDGE, Mass., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on September 27, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 110,000 restricted stock unit awards (RSUs)
In this article, we will take a look at the 25 biggest stocks with negative beta. To see more such companies, go directly to 5 Biggest Stocks with Negative Beta. Stock markets were in see-saw mode before the Fed’s September decision on rate hikes. Markets gained on September 11 after positive data from China and […]
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
In this article, we will take a look at the most innovative companies in America. If you want to explore similar companies, you can go to 5 Most Innovative Companies in America. Innovation and American Companies Innovation comes with new and creative ideas that bring a healthy change in society. Innovation in business and technology […]
Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk, on Thursday said it had closed its acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal valued at $462 million. The acquisition of Paratek Pharmaceuticals, which was announced in early June, is Novo Holdings' largest individual investment in antimicrobial resistance therapies to date, it said in a statement. Novo Holdings, which controls 76% of the votes in Denmark's Novo Nordisk last week announced a m...
CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats. The Company's lead commercial product, NUZYRA® (omadacycline),
CAMBRIDGE, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at Cantor Fitzgerald’s Gl
The FDA filing is supported by data from a late-stage study that shows that Merck's (MRK) Welireg achieved statistically significant and clinically meaningful improvement in progression-free survival.
Key Insights Significantly high institutional ownership implies Paratek Pharmaceuticals' stock price is sensitive to...
BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek’s special meeting of stockholders, in connection with the previously announced definitive agreemen